
    
      Participants aged 1 year to less than 5 years will be randomized to receive one injection of
      IMOJEV® either as a primary vaccination or as a booster. Safety data will be collected for 60
      days after IMOJEV® vaccination. The duration of each subject's participation in the trial
      will be 60 days.
    
  